Nørgaard-Pedersen B, Schultz H, Arends J, Brincker H, Jacobsen G K, Lindeløv B, Rørth M, Svennekjaer I L
Ann N Y Acad Sci. 1983;417:390-9. doi: 10.1111/j.1749-6632.1983.tb32881.x.
The DATECA Project was started in January 1976 and includes all patients with testicular cancer in Denmark. During the first 6 years, 1246 patients entered the joint protocol for histology, staging, management, and clinical use of tumor markers. Only 746 DATECA patients fulfilled the claims for being ideally monitored with preoperative as well as postoperative serologic marker determinations. The overall prevalence of marker positivity, that is, elevated preoperative values of alpha-fetoprotein (AFP) and/or human chorionic gonadotrophin (HCG) was 8% for patients with seminoma and 63% for patients with nonseminomatous disease. The prevalence of increased marker concentration in serum was correlated to stage (higher prevalence in higher stages) and to prognosis (marker-negative patients had a better prognosis than did marker-positive patients). An increased concentration of AFP or HCG was correlated with the presence of a primary endodermal sinus tumor and choriocarcinoma component, respectively.
DATECA项目始于1976年1月，涵盖丹麦所有睾丸癌患者。在最初的6年里，1246名患者进入了关于组织学、分期、治疗及肿瘤标志物临床应用的联合方案。仅有746名DATECA患者符合术前及术后血清学标志物检测进行理想监测的要求。标志物阳性的总体患病率，即术前甲胎蛋白（AFP）和/或人绒毛膜促性腺激素（HCG）值升高，精原细胞瘤患者为8%，非精原细胞瘤患者为63%。血清中标志物浓度升高的患病率与分期（分期越高患病率越高）及预后相关（标志物阴性患者的预后优于标志物阳性患者）。AFP或HCG浓度升高分别与原发性内胚窦瘤和绒毛膜癌成分的存在相关。
